A Prospective, Open-label Trial of Two Abacavir/Lamivudine Based Regimen (ABC/3TC + Darunavir/Ritonavir or ABC/3TC + Raltegravir) in Late Presenter naïve Patients (With CD4 Count <200 Cells/µL - Advanced HIV Disease)
Phase of Trial: Phase III
Latest Information Update: 04 Nov 2016
At a glance
- Drugs Lamivudine/abacavir (Primary) ; Darunavir; Raltegravir; Ritonavir
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 25 Oct 2016 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2016.
- 25 Oct 2016 Status changed from not yet recruiting to recruiting.